Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Revenue (2016 - 2025)

Cytosorbents' Revenue history spans 15 years, with the latest figure at $9.2 million for Q4 2025.

  • Quarterly results put Revenue at $9.2 million for Q4 2025, up 0.91% from a year ago — trailing twelve months through Dec 2025 was $37.1 million (up 4.12% YoY), and the annual figure for FY2025 was $37.1 million, up 4.12%.
  • Revenue for Q4 2025 was $9.2 million at Cytosorbents, down from $9.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $12.0 million in Q2 2021 to a low of $8.1 million in Q3 2022.
  • The 5-year median for Revenue is $9.2 million (2024), against an average of $9.3 million.
  • The sharpest move saw Revenue increased 22.76% in 2021, then dropped 29.35% in 2022.
  • Year by year, Revenue stood at $10.8 million in 2021, then decreased by 12.91% to $9.4 million in 2022, then fell by 7.69% to $8.7 million in 2023, then rose by 5.57% to $9.2 million in 2024, then grew by 0.91% to $9.2 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $9.2 million, $9.5 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.